Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis
ESC Heart Failure · 01.08.2025 · 12 (4) · 2969-2975
DOI: 10.1002/ehf2.15311 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 28.04.2025. Verfasst von Julia Vogel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Delayed Diagnosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims and Background Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR-CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression. The study aims to assess delays in diagnosis in ATTR-CM patients.
Methods
Patients with ATTR-CM receiving transthyretin stabilizer therapy at the West German Amyloidosis Center (01/2018–12/2023) were included. Clinical, laboratory, and imaging data were analysed. Diagnostic timelines were compared across two periods (2018–2020 and 2021–2023).
Results
After screening 254 patients, 154 were included in the analysis. ATTRwt was the most common form (96.8%). The median age was 80 (76–83) years, 87% were male and 46.6% were NYHA class ≥III. Time to diagnosis decreased from 398 to 277 days in the second period (P < 0.001). The median duration from diagnosis to stabilizer therapy was 84 (44–160) days, reducing from 111 (55–237) days in the first period to 57 (36–102) days in the second period (P < 0.001). Patients diagnosed in the first period had lower LVEF (P < 0.001) and more advanced NAC stages (P = 0.004). More women were diagnosed in the second period (P = 0.010).
Conclusion
ATTR-CM is associated with diagnostic delays from initial suspicion to therapy initiation. While diagnostic and treatment timelines have improved, enhanced awareness, supraregional networks, specialized centres and focused education are essential to improve diagnosis and outcomes. Increasing awareness has led to patients being diagnosed at earlier disease stages, underscoring the potential to positively impact patient prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Essen, Germany.
- West German Amyloidosis Center, University Hospital Essen, Essen, Germany.
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany.
Zitieren
APA
Vogel, J., Jura, S., Settelmeier, S., Buehning, F., Lerchner, T., Carpinteiro, A., Rassaf, T., & Michel, L. (2025). Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis. ESC Heart Failure, 12(4), 2969-2975. https://doi.org/10.1002/ehf2.15311
Vancouver
Vogel J, Jura S, Settelmeier S, Buehning F, Lerchner T, Carpinteiro A, et al. Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis. ESC Heart Failure. 2025;12(4):2969-2975. doi:10.1002/ehf2.15311
BibTeX
@article{Vogel2025,
author = {Vogel, Julia and Jura, Sophia and Settelmeier, Stephan and Buehning, Florian and Lerchner, Tobias and Carpinteiro, Alexander and Rassaf, Tienush and Michel, Lars},
title = {Delays in Diagnosis and Treatment of ATTR Cardiac Amyloidosis: A Real-World Data Analysis},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {4},
pages = {2969--2975},
doi = {10.1002/ehf2.15311}
}
EUVIMED